Trials / Completed
CompletedNCT01200394
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 256 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00489791 | Tablet, 20 mg once daily for 12 weeks |
| DRUG | Placebo | Tablet, placebo once daily for 12 weeks |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2013-07-01
- Completion
- 2013-08-01
- First posted
- 2010-09-13
- Last updated
- 2019-03-12
- Results posted
- 2019-03-12
Locations
160 sites across 15 countries: United States, Australia, Canada, Denmark, Hong Kong, India, Malaysia, Mexico, Poland, Serbia, Slovakia, South Africa, South Korea, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01200394. Inclusion in this directory is not an endorsement.